Metacycloprodigiosin is an antibiotic that has been shownto suppress T-cell proliferation induced by concanavalin A in vitro. Weexamined the effect of metacycloprodigiosin on murine allogeneic skin and heart transplantation models, and compared graft rejection with donor-specific cytotoxic T-cells and antibody activity. The antibiotic slightly prolonged the survival of C57B1/6 heart and skin grafts in BALB/cmice, although the effect was less than that of cyclosporin A. The effect was more evident in Bml (H-2D mutant) skin grafts on G57B1/6 hosts or in a minor histocompatibility antigen-mismatched model. In contrast, metacycloprodigiosin suppressed anti-graft cytotoxic T-cell activity of BALB/c spleen grafted with C57B1/6 skin as comparable to cyclosporin A, but had only partial effect on antibody production. Thus, metacycloprodigiosin is more effective in reducing splenic cytotoxic T-cell activity than in prolonging murine skin or cardiac allografts.
Rejection of foreign grafts by allogeneic
hosts is a problem that has fundamental and clinical relevance. T-lymphocytes have been shown to be important for initiating allograft rejection1?2). Subsequent to initial T-cell recognition, a number of effector mechanisms may be involved in rejection, including nonspecific inflammatory reactions and antigen-specific responses mediated by T-cells and B-cells. Amongthese, cytotoxic T lymphocytes (CTL) are considered to be a leading candidate as an effector for rejection3'4). However the conclusion that CTL is the major effector in allograft rejection has been questioned in a number of studies, and the effector mechanism mediating the actual tissue destruction has been a source of controversy5~9).
Prodigiosin 25-C (PrG 25-C) and metacycloprodigiosin (MC-PrG) are red pigments produced by microbes including Streptomyces and Serratia1Otl l). These antibiotics specifically inhibited T-cell mediated mitogenic responses in the screening program using mitogenic responses of splenocytes12).
Further studies demonstrated that PrG 25-C inhibited CTL induction in vivo without affecting antibody production, including antibodies against T-cell-dependent and T-cell-independent antigens13?14 . In this paper, we examined the effect of MC-PrGon CTLactivity and graft rejection in allogeneic heart and skin transplantation models and found that MC-PrGonly slightly prolonged survival time of grafts in spite of strong inhibition of splenic CTLactivity.
Materials and Methods

Mice
All the mice used in these experiments were females, 6~10 week of age, obtained from the Animal Production Facility, NCI, Frederick, MD. Pregnant mice were received in our animal facility at two weeks of gestation. Hearts from the newbornmice were harvested within two days of delivery for the transplantation. Chemicals MC-PrG was purified from culture broth of Streptomyces hiroshimensis as described previously12).
MC-PrGwas dissolved in DMSO at lOmg/ml, and the solution was diluted to 2 mg/ml with phosphate buffered saline (PBS, Gibco Lab., Gland Island, NY) containing 0.5% Tween 20 immediately before ip injection of 0.2ml of the solution. Cyclosporin A (CsA) was kindly provided by Dr. David Winter (Sandoz, Hanover, NJ). The drug was diluted in olive oil (Sigma, St. Louis, MO) to 15mg/ml and 0.05ml of the material was injected ip.
Transplantation
Skin grafting was performed as described previously1 5) with slight modification. Therecipients of the transplantation were anesthetized by the ip injection of 0.15 ml of PBS containing 20 mg/ml Ketamine (Aveco, Ft. Dodge, IO) and 0.4 mg/ml Xylazine (Haver, Shawnee, KA). Tail skin was removed and processed in about 50mm2square and engrafted to the left flank of the recipients. Bandages were removed on day 5 and the grafts were monitored daily until rejection (defined as loss of >50% of the grafted tissue).
Heart grafting was performed according to the method reported by Fulmer et al.21) . The hearts of newborn mice sacrificed by decapitation were bisected along the longitudinal axis with a scalpel and each half was transplanted into a pocket prepared in the left ear of the adult recipients. The pulsatile of the grafts were observed under a stereomicroscope every other day using methoxylflurane (Pitman-Moore, Mundelein, IL) for anesthesia and graft rejection was determined by the cessation of beating.
CTL Assay Spleens of recipients were removedand teased to make single cell suspension and incubated with 51Cr-labeled target cells (5 x 103cells/well) for 4 hours at 37°C in 7% CO2atmosphere in RPMI1640medium supplemented with 5% fetal calf serum as described previously13). The isotope released in the culture supernatant was 87 measured using a y-counter. Maximum and spontaneous isotope release was determined as the cpmin the absence of effectors and in the presence of 1% SDS, respectively. Percent lysis was calculated by the formula.
% lysis = experimental cpm-spontaneous cpm maximum cpm-spontaneous cpm xlOO Anti-graft Antibody Titer 51Cr-labeled splenocytes (1.25 x 105 cells) were incubated with serum from the allograft recipients which was serially diluted with medium in 96-well flat-bottom microtiter plates, as described previously16). After incubating for 15 minutes at 37°C, the plates were centrifuged at 1,000 rpm for 5 minutes and the pellet was further incubated with 10-fold diluted non-toxic rabbit complement for 45 minutes at 37°C. The radioactivity of the supernatant was measured and %lysis was calculated using above formula.
Statistics
Statistical analysis was performed by using the one tailed Student's t-test and P< 0.05 was taken as the level of significance.
Results
To confirm the effect of MC-PrGwe induced CTL and antibody against allogeneic cells by ip injection of P815 (H-2d) cells into C57B1/6 mice (H-2b) as reported previously13). As shown in Table 1 , MC-PrG significantly suppressed anti-P815 CTL activity, whereas it had no effect on antibody titer against allogeneic spleen cells.
In contrast, CsA suppressed both CTL activity and antibody titer. Thus MC-PrG, like PrG 25-C, preferentially suppressed CTL. Treatment with higher dose of MC-PrGresulted in the death of some mice.
Tail skin of C57B1/6 mice was engrafted on the flanks of BALB/cmice. MC-PrGwas administered every other day (Table 2, exp. 1). First, we used 1 mg/kg ofMC-PrG, as we used for P815-immunized mice and observed no significant prolonged survival of the grafts. Anincrease in the dose to 2mg/kg of MC-PrGresulted in some toxicity as mice exhibited a decrease in body weight but no death during the experiment. However, the antibiotic did not show significant suppressive activity in the skin graft model, although a slight prolongation of survival was consistently observed. In contrast, CsAshowed a protective effect. Allogeneic skin grafts of the CsAtreated mice were not rejected during the experiments.
A similar result was obtained in the heart transplant model (exp. 2). MC-PrGagain prolonged graft survival only slightly, whereas CsAprevented rejection. Thus, the lack of extensive graft prolongation by MC-PrGwas C57B1/6 (H-2b) mice (3 mice/group) were immunized ip with P815 (H-2d, 2 x 107 cells) and treated ip with MC-PrG (1 mg/kg) every other day or with CsA (30mg/kg) every day from 24 hours after the immunization. Mice were killed on day 10 and CTL activity against P8 1 5 of pooled splenocytes or antibody activity of pooled serum were determined. Values are mean + SD of triplicate culture. a %Lysis at effector to target ratio at 50:1 and 12.5: 1. b %Lysis of BALB/c splenocytes treated with 4%or 1%serum. Table 2 . Prolongation of graft survival by MC-PrG. BALB/c (H-2d, 3 mice per group) were engrafted with C57B1/6 skin (H-2b) and treated ip with MC-PrG (2mg/kg) every other day or CsA (30mg/kg) every day from 24 hours after the transplantation.
Mice were killed on day 10 and CTLactivity against EL-4 (H-2b) of pooled splenocytes and antibody activity of pooled serum were determined. Values are mean + SDof triplicate culture. a %Lysis at effector to target ratio 100: 1 and 50: 1. b % Lysis of C57B1/6 splenocytes treated with 10% or 3% of serum.
c Less than spontaneous cpm. VOL.49 NO. 1 THE JOURNAL OF ANTIBIOTICS independent of the tissue transplanted. Because majority of CTL is CD8+cells restricted by class I MHC,the effect of MC-PrGwas compared in class I-or class II-mismatched transplants, using mice expressing MHCmutation. A significant prolongation of graft survival by MC-PrGwas observed with class I-mismatched model (Bml into C57B1/6, exp.3) but not in the class II-mismatched model (Bml2 into C57B1/6, exp. 4). However, such prolongation was not observed in the class I-mismatched model using congeneic mice that involved an H-2D and L difference (exp. 5). Finally we used the antibiotic in a minor histocompatibility antigen-mismatched model (B10.BR into C3D2F1) and observed a significant prolongation of the allografts. Since the rejection of minor histocompatibility antigendifferent graft is dependent on CD4+ T-cells22~25), the result suggests that the effectiveness of MC-PrGis dependent on the strength of the rejection and not on differences in MHCtype.
We determined the CTL activity of spleen from BALB/c mice that were grafted with C57B1/6 skin. The CTL activity in the spleen was observed maximally 10 days after transplantation, and the activity declined gradually thereafter (data not shown). MC-PrGagain inhibited the CTL activity on day 10, which was comparable to that of CsA (Table 3) . Antibody titer against allogeneic spleen cells was also reduced by MC-PrGtreatment, but was not as dramatic as the effect of CsA on antibody production.
Discussion
Wecompared the effect of MC-PrGin both heart and skin transplantation models and found that the antibiotic significantly suppressed the CTLinduced by allogeneic graft as well as allogeneic tumor immunization. Although the antibiotic prolonged the graft survival, the effect was low compared with CsA. It prolonged the graft survival only in strain combinations that exhibit weak rejection patterns, such as Bml/C57Bl/6 or minor histocompatibility antigen-mismatched differences. It is unlikely that residual negligible CTL activity is sufficient to effect rejection, because CsA which suppressed CTLactivity as strongly as MC-PrGcompletely prevented graft rejection. Our results suggest that suppression of splenic CTL is not sufficient for prolongation of graft rejection involving strong immunologic differences.
These results are consistent with previous reports that anti-CD4 antibody is more effective than anti-CD8 antibody for suppression of graft rejection23~26), and that MHC-deficient mice still reject allografts despite the lack of specific CTL activity27). This latter report suggests that some effectors other than T-cells also play 89 significant roles in graft rejection. Since antibody against tumor necrosis factor, an major cytotoxic effector molecule of macrophages, effectively suppresses graft rejection28>29), immunosuppressants that suppress macrophage function might help the suppressive activity of MC-PrG.
PrG 25-C inhibits intracellular acidification through inhibition of proton pumping of vacuolar-type H+-ATPase18). We found that an inhibitor of vacuolar-type H+-ATPasealso inhibits the acidification of cytotoxic granules and induces destruction of their structure and degradation of perforin20), one of the effector molecules in the granules30). However, it affected neither granule exocytosis in response to stimulation of T-cell receptor nor granzyme activity in the granules20). Recent reports suggest that Fas-dependent pathway contributes to killing activity of CTLin addition to perforin dependent pathway31 '32) . Since PrG 25-C does not affect Fasdependent pathway (T. Kataoka, unpublished result), it is possible that molecules other than perforin which are active even in the presence of MC-PrGinduce the rejection.
The suppressive effect of MC-PrGis dependent on the kind of allo-stimulation.
CTL induced by P815-immunization was almost completely inhibited by 0.5 mg/kg whereas this dose only partially suppressed CTL induced by allogeneic skin or heart (data not shown). Since bioavailability of the antibiotic might differ from tissue to tissue, it is possible that CTL in the graft is sufficiently active to provoke rejection even if that in spleen is suppressed. Although MC-PrG exhibits high toxicity which prevented our treatment of animals with higher doses, chemical modification of the antibiotic might improve the bioavailability and toxicity, and thus the efficacy for suppression of graft rejection. Annu. Rev. Immunol. 10: 333-358, 1992 2) Lafferty, K. J.; S. J. Prowse, C. J. Simeonovic & H. S.
Warren: Immunobiology of tissue transplantation: a return to the passenger leukocyte concept. Annu. Rev. Immunol. 1: 143-173, 1983 3) Mintz, B 
